ESMO update: upper gastrointestinal cancer
This study led to the approval of trastuzumab–deruxtecan as second-line therapy in patients with Her2-positive gastric and gastroesophageal junction tumors who have experienced disease progression after first-line trastuzumab-containing therapy.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Study